ResearcherSingHealthActive in the last 2 years
Ye Xin Koh
Matched on ORCID iD 0000-0001-5006-4174; OpenAlex author ID A5071784532. Sources: OpenAlex.
Their work
- Papers
- 10 (first author 0, last author 7)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 9
2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 5 papers · 2026: 3 papers
Papers 10
- Pancreatic cancer burden across Southeast Asia from 1990 to 2021: An analysis of incidence and mortality based on the global burden of disease study 2021. Co-author DOI 10.1016/j.pan.2025.09.031↗
- Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequent… Last author DOI 10.1016/j.surg.2025.109872↗
- Exploring the role of immunotherapy and radiotherapy in the adjuvant landscape of resected pancreatic cancer. Last author DOI 10.21037/tgh-2026-0026↗
- SEER-based evaluation of lymph node yield as a prognostic indicator of cancer-specific survival in nonmetastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2025.05.008↗
- Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and Meta-analysis of Latest Randomized Contr… Last author DOI 10.1245/s10434-024-16674-y↗
- ASO Author Reflections: Resectable Pancreatic Cancer Treatment to be Optimized with Accurate Biological Aggressiveness Staging and Risk Stratification in the F… Last author DOI 10.1245/s10434-024-16812-6↗
- Surgery and neoadjuvant therapy in locally advanced pancreatic cancer: an umbrella review of survival, resection outcomes, and cost-effectiveness. Last author DOI 10.21037/gs-24-421↗
- Survival Outcomes in Nonmetastatic pT4 Pancreatic Ductal Adenocarcinoma: A SEER Database Analysis Comparing Neoadjuvant Therapy and Upfront Surgery with Propen… Last author DOI 10.31557/apjcp.2025.26.3.847↗
- Resected pancreatic adenocarcinoma: An Asian institution's experience. Co-author DOI 10.1002/cnr2.1393↗
- Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal ade… Co-author DOI 10.1245/s10434-014-3639-0↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Brian K. P. Goh · 10 shared papers, 2014–2026 · strength 2.83
- Paper Exploring the role of immunotherapy and radiotherapy in the adjuvant landscape of resected pancreatic cancer. DOI 10.21037/tgh-2026-0026↗
- Paper ASO Author Reflections: Resectable Pancreatic Cancer Treatment to be Optimized with Accurate Biological Aggressiveness … DOI 10.1245/s10434-024-16812-6↗
- Paper Survival Outcomes in Nonmetastatic pT4 Pancreatic Ductal Adenocarcinoma: A SEER Database Analysis Comparing Neoadjuvant… DOI 10.31557/apjcp.2025.26.3.847↗
- Hwee Leong Tan · 6 shared papers, 2025–2026 · strength 1.88
- Paper Exploring the role of immunotherapy and radiotherapy in the adjuvant landscape of resected pancreatic cancer. DOI 10.21037/tgh-2026-0026↗
- Paper SEER-based evaluation of lymph node yield as a prognostic indicator of cancer-specific survival in nonmetastatic pancre… DOI 10.1016/j.pan.2025.05.008↗
- Paper Surgery and neoadjuvant therapy in locally advanced pancreatic cancer: an umbrella review of survival, resection outcom… DOI 10.21037/gs-24-421↗
- Yun Zhao · 5 shared papers, 2025–2026 · strength 1.49
- Paper Survival Outcomes in Nonmetastatic pT4 Pancreatic Ductal Adenocarcinoma: A SEER Database Analysis Comparing Neoadjuvant… DOI 10.31557/apjcp.2025.26.3.847↗
- Paper SEER-based evaluation of lymph node yield as a prognostic indicator of cancer-specific survival in nonmetastatic pancre… DOI 10.1016/j.pan.2025.05.008↗
- Paper Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-pati… DOI 10.1016/j.surg.2025.109872↗
- Anna Ho Yin Chan · 2 shared papers, 2025 · strength 0.67
- Paper ASO Author Reflections: Resectable Pancreatic Cancer Treatment to be Optimized with Accurate Biological Aggressiveness … DOI 10.1245/s10434-024-16812-6↗
- Paper Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and … DOI 10.1245/s10434-024-16674-y↗
- Kennedy Yao Yi Ng · 3 shared papers, 2021–2026 · strength 0.65
- Paper Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-pati… DOI 10.1016/j.surg.2025.109872↗
- Paper Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and … DOI 10.1245/s10434-024-16674-y↗
- Paper Resected pancreatic adenocarcinoma: An Asian institution's experience. DOI 10.1002/cnr2.1393↗
- David Wai-Meng Tai · 3 shared papers, 2021–2026 · strength 0.65
- Paper Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-pati… DOI 10.1016/j.surg.2025.109872↗
- Paper Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and … DOI 10.1245/s10434-024-16674-y↗
- Paper Resected pancreatic adenocarcinoma: An Asian institution's experience. DOI 10.1002/cnr2.1393↗
- Yun Zhao · 1 shared paper, 2025 · strength 0.33
- Ser Yee Lee · 1 shared paper, 2021 · strength 0.10
- Pierce K. H. Chow · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.